IMNM
Immunome, Inc.23.48
+0.84+3.71%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
2.15BP/E (TTM)
-Basic EPS (TTM)
-2.96Dividend Yield
0%Recent Filings
8-K
8-K
10-Q
8-K
Immunome Q2 loss widens
Immunome reported a Q2 2025 net loss of $43.4 million, up from $36.1 million last year, driven by $40.5 million in R&D expenses as clinical programs advance. Cash reserves hit $268.0 million, funding operations into 2027. Pipeline momentum builds: Phase 3 RINGSIDE topline data due by year-end; IM-1021 dosed third cohort; IM-3050 trial starts soon. Yet risks loom if trials falter.
10-Q
Q2 FY2025 results
Immunome expanded its lease footprint in Bothell, Washington, securing the full 23,346 square feet across two buildings through amendments effective June 11, 2025, while boosting the tenant improvement allowance by an undisclosed amount to be amortized into base rent starting April 1, 2026. This move aligns with the company's clinical-stage biotech focus, providing dedicated space for R&D without immediate revenue impact but supporting long-term operational scaling. Liquidity remains bolstered by the existing $XXXM letter of credit as security, with no changes to debt or cash positions disclosed. The amendments include rent abatement periods and parking expansions, yet regulatory hurdles in drug development pose ongoing risks to execution.
BOLT
Bolt Biotherapeutics, Inc.
5.45+0.06
IMA
ImageneBio, Inc.
6.25+0.08
IMNN
Imunon, Inc.
3.88-0.09
IMRX
Immuneering Corporation
5.74-0.04
IMTX
Immatics N.V.
10.09+0.11
IMUC
EOM Pharmaceutical Holdings Inc
0.18+0.00
IMUX
Immunic, Inc.
0.60-0.01
INMB
INmune Bio Inc.
1.89-0.02
IOBT
IO Biotech, Inc.
0.69-0.02
TIL
Instil Bio, Inc.
11.25+0.13